Protagenic Therapeutics, Inc. 8-K Report: Key Financial Insights & Updates

Based on the provided XML section of the financial report, here are the key insights and information extracted:

1. Entity Information:

• Name: Protagenic Therapeutics, Inc.
• CIK: 0001022899
• Address: 149 Fifth Avenue, Suite 500, New York, NY 10010
• Phone: 212-994-8200

2. Filing Details:

• Form Type: 8-K
• Filing Date: February 21, 2025
• SEC File Number: 001-12555
• IRS Employer Number: 06-1390025

3. Stock Information:

• Common Stock Ticker: PTIX (listed on NASDAQ)
• Common Stock Warrants Ticker: PTIXW (listed on NASDAQ)

4. Financial Context:

• Period of Reporting: The report is for the date February 21, 2025.
• Stock Classes: The report includes information related to:
• • Common Stock
  • Common Stock Warrants

5. Units of Measure:

• Currency: USD (United States Dollar)
• Measurement Units: Shares and USD per share

6. Miscellaneous:

• The document utilizes XBRL format, which is standard for SEC filings, indicating structured data presentation for financial reporting.

Insights:

• The filing indicates that Protagenic Therapeutics is actively engaged in reporting its financial position or significant events as of a specific date.
• The presence of both common stock and warrants suggests potential activities related to fundraising or capital structure adjustments.
• Investors and analysts should monitor this filing for any implications regarding stock performance and corporate actions, particularly surrounding the timing of the report.

Conclusion:

This financial report provides a snapshot of Protagenic Therapeutics, Inc.'s stock structure and recent filing activities. Stakeholders should review the detailed contents of the 8-K filing for a comprehensive understanding of the company's current financial standing and any significant corporate developments disclosed.